Alzheimer's Research in Space: Studying Neurodegeneration in Microgravity
Photo: Mikhail Nilov / Pexels
Alzheimer's disease develops over decades, which is exactly why it is so hard to study on Earth. On the International Space Station (ISS), researchers have found that human brain organoids — pea-sized clusters of lab-grown neural tissue — mature faster in microgravity than identical organoids grown on the ground, with molecular markers suggesting the cells had effectively aged years within days (NASA, ISS National Lab). Separately, ISS experiments on the actual Alzheimer's protein, amyloid-beta, found the opposite effect: its clumping into disease-associated fibrils slows down dramatically without gravity (npj Microgravity, 2020). Together, these two strands of research are turning the ISS into an unlikely laboratory for one of medicine's hardest problems.
Key Takeaways
- Human brain organoids grown on the ISS mature faster than ground controls, with gene-expression patterns resembling more advanced developmental stages after just weeks in orbit
- Amyloid-beta, the protein that clumps into plaques in Alzheimer's disease, forms its aggregate structures (fibrils) much more slowly in microgravity, not faster — a finding that runs counter to some earlier assumptions
- The ISS National Lab has flown disease-specific organoids derived from patients with Alzheimer's, Parkinson's disease, and multiple sclerosis to study neurodegeneration mechanisms directly
- A biotech startup, Axonis Therapeutics, used ISS-grown brain organoids to test a gene therapy candidate for neurological disease, moving it closer to clinical trials
- Astronauts themselves are not developing Alzheimer's in orbit — the research uses cultured cells and proteins, and any changes to astronaut cognition or brain structure are a separate, much smaller effect studied through programs like NASA's Twins Study
Why researchers went looking for Alzheimer's answers off-planet
Alzheimer's disease affects an estimated 6.7 million Americans age 65 and older, according to the Alzheimer's Association's 2023 facts and figures report, and that number is projected to nearly double by 2050 as the population ages (Alzheimer's Association). Despite decades of research investment, most Alzheimer's drug candidates that enter clinical trials fail. Part of the problem is timescale: the disease's defining features, amyloid-beta plaques and tau protein tangles, accumulate over ten to twenty years before symptoms even appear. Watching that process unfold in a petri dish or a mouse brain on Earth is slow, expensive, and often doesn't translate to human biology.
Space offered an unexpected shortcut. NASA and commercial partners have spent more than a decade using the ISS National Laboratory to study how the near-absence of gravity affects basic biology, from muscle wasting to immune function to stem cell behavior. Neural tissue turned out to be one of the more striking examples. When cells no longer have to contend with gravitational load, the mechanical and fluidic environment inside a cell culture changes: nutrients diffuse differently, cells self-assemble into three-dimensional shapes more like real tissue, and developmental signaling pathways shift. That combination made brain organoids — three-dimensional aggregates of neurons and support cells derived from human induced pluripotent stem cells (iPSCs, adult cells reprogrammed back into a stem-cell-like state) — a natural candidate for orbital experiments.
The first wave of neurodegeneration-focused missions launched through the ISS National Lab and NASA's In-Space Production Applications (InSPA) program, in partnership with organizations including the National Stem Cell Foundation, Scripps Research Institute, and the New York Stem Cell Foundation. These missions sent iPSC-derived neural organoids, including some carrying disease-associated mutations from actual patients, to the station for weeks at a time before returning them to Earth-based labs for detailed analysis (ISS National Lab).
How brain organoids and amyloid protein actually travel to orbit and back
Two distinct experimental approaches have driven most of the Alzheimer's-relevant work on the ISS: cell-based organoid studies and cell-free protein studies. They ask different questions and, notably, have produced opposite directional findings, which is a useful reminder that "microgravity accelerates disease" is an oversimplification.
Organoid missions. Researchers first grow iPSC-derived neural organoids on the ground for several weeks, allowing them to form basic three-dimensional structure. Some organoids are cortical (mimicking the brain's outer layer), others dopaminergic (relevant to Parkinson's disease), and more recent missions have incorporated microglia, the brain's resident immune cells, to study neuroinflammation. The organoids are packed into automated bioreactor hardware that supplies nutrients, removes waste, and maintains temperature without a human tending them, since ISS crew time is limited and expensive. A SpaceX Cargo Dragon or similar vehicle carries the hardware to the station, where it operates for roughly one month before returning to Earth for analysis. Identical organoids stay in an incubator on the ground as a matched control (Stem Cells Translational Medicine, 2024).
Amyloid-beta protein missions. These experiments skip living cells entirely and study the protein itself. In the landmark 2020 npj Microgravity study, researchers flew frozen samples of Aβ(1-40), a 40-amino-acid fragment of amyloid-beta, to the ISS between December 2017 and January 2018. Once aboard, the samples were thawed and incubated at human body temperature (37°C, 98.6°F) for periods ranging from six hours to nine days, then refrozen for return to Earth. Back on the ground, researchers used thioflavin T fluorescence (a dye that lights up when it binds to the misfolded fibril structures characteristic of Alzheimer's plaques) and cryo-electron microscopy to measure how far the protein had progressed toward forming disease-like fibrils (npj Microgravity, 2020).
Why would gravity affect protein folding at all?
Gravity drives sedimentation and convection, the slow settling and mixing that happens in any liquid on Earth. Remove gravity, and a protein solution behaves more like a still, diffusion-only system. For amyloid-beta, that changes the physical process of nucleation, the first step where a handful of misfolded protein molecules clump together to start a fibril. Slower, more uniform diffusion appears to produce fewer nucleation events and more uniform crystal-like structures.
What the results actually showed, and where they surprised researchers
The organoid and protein experiments told two different, non-contradictory stories about how the absence of gravity touches neurodegeneration biology.
Accelerated neural maturation in organoids. In the Scripps Research Institute and New York Stem Cell Foundation study led by co-senior author Jeanne Loring, brain organoids spent about one month in orbit before returning for analysis. Gene expression profiling showed the space-grown organoids had significantly higher expression of genes associated with neural maturity and lower expression of genes associated with cell proliferation, meaning the cells behaved as though they were further along in development than their Earth-bound twins of the same chronological age (Neuroscience News coverage of the study, 2024). Somewhat counterintuitively, inflammation and cellular-stress gene signatures were lower than researchers had anticipated going in, not higher, and all organoids in the study remained viable throughout the mission.
Rapid self-assembly for drug testing. Axonis Therapeutics, a biotechnology startup developing viral-vector gene therapy for neurological conditions including Alzheimer's, Parkinson's disease, and spinal cord injury, used ISS National Lab facilities to grow mature 3D brain organoids from cells in a matter of days, a self-assembly speed the company says is difficult to reproduce on Earth. The company used the space-grown tissue to test its gene therapy candidate in a more mature, more realistic brain model than ground-based culture typically allows, a step that helped de-risk the therapeutic ahead of further development (ISS National Lab case study; PR Newswire, 2024).
Slower, more ordered amyloid-beta fibril formation. The 2020 npj Microgravity study found the opposite direction of effect from what a casual reader might expect. Aβ(1-40) protein incubated on the ISS reached the thioflavin T fluorescence plateau, indicating fibril formation was essentially complete, in more than nine days. The identical ground control reached that same plateau in about three days. Microgravity did not accelerate amyloid aggregation; it slowed it substantially. The fibrils that did form in space also looked structurally different: roughly 80% were a narrower "Type-1" morphology (6 to 8 nanometers at their twisted crossover points) and 20% were a wider "Type-2" morphology (over 10 nanometers), while ground-grown fibrils were exclusively the Type-1 shape but larger. The researchers concluded that gravity-driven convection normally constrains how amyloid fibrils can form, and removing it reveals a wider range of possible structures (npj Microgravity, 2020).
Disease-specific patient organoids. Building on the initial maturation findings, subsequent ISS National Lab missions carried disease-associated organoids derived from patients with Alzheimer's disease, Parkinson's disease, and primary progressive multiple sclerosis, including organoids with an early-onset Alzheimer's mutation, giving researchers a way to compare how patient-derived tissue behaves in microgravity relative to healthy control tissue (ISS National Lab).
| Experiment type | Institutions involved | What changed in microgravity | Source |
|---|---|---|---|
| iPSC-derived cortical/dopaminergic organoids | Scripps Research Institute, New York Stem Cell Foundation | Faster neural maturation; higher maturity gene expression; lower-than-expected inflammation signatures | Stem Cells Translational Medicine, 2024 |
| Disease-associated patient organoids (Alzheimer's, Parkinson's, MS) | National Stem Cell Foundation, ISS National Lab, NASA | First platform for studying patient-specific neurodegeneration mutations in orbit | ISS National Lab, 2024 |
| Amyloid-beta Aβ(1-40) fibril formation | Japan Aerospace Exploration Agency (JAXA)-supported ISS mission | Fibril formation roughly 3x slower; distinct fibril morphologies emerged | npj Microgravity, 2020 |
| Gene therapy testing in mature organoids | Axonis Therapeutics, ISS National Lab | Rapid organoid self-assembly (days, not weeks) enabled therapeutic testing in mature tissue | ISS National Lab case study, 2024 |
| Table: ISS-based neurodegeneration and Alzheimer's-relevant experiments and their headline findings. |
Why this matters beyond the space station
The practical value of this research is less about any single discovery and more about the platform itself: a way to compress or manipulate biological timescales that are otherwise fixed on Earth.
A faster developmental model. If microgravity reliably accelerates neural maturation, researchers get organoids that behave like "older" tissue in a shorter experimental window. That matters for late-onset diseases like Alzheimer's, where the interesting biology often only shows up in aged neurons, something that is notoriously hard to model with young, lab-grown cells on the ground.
A cleaner window into protein misfolding. The amyloid-beta result is arguably the more scientifically important one, precisely because it defied the simple "space speeds everything up" narrative. By removing gravity-driven convection, researchers isolated the underlying molecular physics of fibril nucleation from the confounding effects of fluid mixing. That gives structural biologists a cleaner picture of the earliest, most therapeutically relevant steps in plaque formation, the stage where an eventual drug would need to intervene.
A manufacturing and testing shortcut for biotech. For a company like Axonis, the appeal wasn't the physics, it was speed and quality: organoids that would take much longer to reach usable maturity on Earth self-assembled within days on the ISS, letting the company test a real therapeutic candidate against realistic tissue sooner. As commercial space stations and more frequent, lower-cost launch options come online later this decade, this kind of "space as R&D infrastructure" approach is likely to expand well beyond one company's gene therapy program.
A path to better-controlled biomarker discovery. Comparing gene expression in space-matured organoids to ground controls gives researchers a naturally occurring experimental perturbation, a way to see which genes shift with accelerated maturation, that can help refine which molecular markers actually track meaningful brain aging versus which are just noise.
Common confusions: what this research does not show
It is easy to read headlines about "Alzheimer's in space" and draw the wrong conclusion, so it's worth being explicit about the boundaries of what has actually been demonstrated.
Astronauts are not getting Alzheimer's disease from spaceflight. None of the organoid or protein studies involve living human brains in orbit, and there is no evidence that astronauts develop Alzheimer's disease pathology from their missions. Real astronaut brain research, most visibly NASA's Twins Study comparing astronaut Scott Kelly to his ground-based identical twin Mark Kelly during a year-long ISS mission, has found separate and much better-characterized effects: postflight cognitive slowing on certain tasks, brain tissue volume and cerebrospinal fluid shifts, and a condition called spaceflight-associated neuro-ocular syndrome (SANS) affecting roughly 40% of astronauts on long-duration missions, caused by headward fluid shifts in microgravity, not amyloid pathology (Science, 2019; npj Microgravity review, 2021).
"Accelerated" does not mean "diseased." The Scripps/NYSCF organoid finding was accelerated neural maturation, not accelerated neurodegeneration. Genes associated with a more mature, less proliferative cell state going up is a normal developmental signature, not automatically a disease signature. Conflating "matures faster" with "gets Alzheimer's faster" overstates what the gene-expression data actually shows.
The amyloid-beta finding cuts against a simple "microgravity is bad for the brain" narrative. If anything, the ISS protein study found fibril formation was slower and more structurally constrained in microgravity, the opposite of what an "acceleration" story would predict. This is a useful check on any framing, including some earlier popular-science coverage, that treats space as uniformly harmful or uniformly disease-accelerating for neural tissue. The real picture is more specific: different biological processes respond to the absence of gravity in different, sometimes opposite, directions.
ISS-tested drug candidates still need full clinical trials. Axonis's ISS-tested gene therapy moved closer to the clinic because of the space work, but "de-risked" is not the same as "approved" or even "in late-stage trials." Any therapeutic that shows promise in an organoid model, space-grown or not, still has to clear standard preclinical toxicology, an Investigational New Drug application with the FDA, and multi-phase human trials before it could reach patients.
Organoids are not full brains. Even mature, disease-specific organoids lack the vasculature, immune surveillance, and whole-organism context of a real aging human brain. Researchers in this field are consistently explicit that organoid findings, whether from space or Earth, need validation in animal models and eventually patient studies before they inform clinical practice.
FAQ
Q: Does spaceflight cause Alzheimer's disease in astronauts? A: No. There is no evidence that astronauts develop Alzheimer's disease from spaceflight. The ISS Alzheimer's research described here uses lab-grown brain organoids and isolated amyloid-beta protein, not living astronaut brains. Documented astronaut brain effects, like SANS and post-mission cognitive changes, are separate phenomena tied to fluid shifts and vestibular adaptation, not Alzheimer's pathology (npj Microgravity review, 2021).
Q: Does microgravity speed up or slow down Alzheimer's-related processes? A: Both, depending on what's being measured. Brain organoids mature faster in microgravity, showing gene-expression patterns of more advanced neural development. But the amyloid-beta protein that forms Alzheimer's plaques actually aggregates about three times more slowly in microgravity than on Earth (npj Microgravity, 2020).
Q: What are brain organoids, exactly? A: Brain organoids are three-dimensional clusters of neurons and support cells grown from induced pluripotent stem cells (iPSCs), adult cells reprogrammed into a stem-cell-like state and then coaxed to grow into brain-like tissue. They are not miniature functioning brains, but they replicate enough real neural structure and gene activity to serve as a research model for development and disease.
Q: Why does removing gravity change how amyloid-beta protein forms fibrils? A: Gravity normally drives sedimentation and convection, the settling and mixing of molecules in a liquid. Without it, the amyloid-beta protein solution behaves as a purely diffusion-driven system, which appears to slow the nucleation step where fibrils begin forming and allows different, more varied fibril structures to emerge (npj Microgravity, 2020).
Q: Has anything from this research actually reached patients? A: Not yet as an approved therapy. Axonis Therapeutics used ISS-grown brain organoids to test a gene therapy candidate for neurological disease and reported that the results helped de-risk the program and attract investment, moving it closer to clinical development, but the therapy still needs to complete standard preclinical and clinical trial phases before it could be approved for patients (ISS National Lab case study).
Q: How long do organoid experiments stay on the ISS? A: Most published missions have run about one month in orbit before the hardware and samples returned to Earth for detailed lab analysis, though timelines vary by mission and by what the automated bioreactor hardware can support (Stem Cells Translational Medicine, 2024).
Q: Are patient-derived Alzheimer's organoids actually being flown, or just healthy control tissue? A: Both. Early missions used healthy iPSC-derived organoids to characterize baseline effects of microgravity on neural tissue. Subsequent ISS National Lab and NASA-sponsored missions have specifically included disease-associated organoids derived from patients with Alzheimer's disease (including an early-onset mutation), Parkinson's disease, and primary progressive multiple sclerosis (ISS National Lab).
Q: Could this research eventually explain why gravity itself matters for brain health on Earth? A: That is one of the open questions driving the field. Because these experiments isolate gravity as a single variable that is otherwise nearly impossible to remove in ground-based labs, they give researchers a rare way to test whether mechanical and fluid-dynamic forces tied to gravity play a previously underappreciated role in normal neural development and in disease-relevant protein behavior.
Q: Is this the same research area as NASA's Twins Study? A: No, though they are related. The Twins Study examined astronaut Scott Kelly's physiology, including brain-relevant measures, during and after a year in space, compared to his twin on the ground. The Alzheimer's organoid and amyloid-beta research discussed here uses lab-grown cells and isolated proteins, not living astronauts, and is run through the ISS National Laboratory's commercial and academic research program rather than NASA's astronaut health monitoring (Science, 2019).
The takeaway
The ISS turned out to be useful for Alzheimer's research not because space is uniformly good or bad for the brain, but because removing gravity as a variable exposes different pieces of neurodegeneration biology in different ways: faster organoid maturation on one hand, slower and more structurally revealing amyloid-beta aggregation on the other. Neither finding is a cure, and none of it means astronauts are at elevated Alzheimer's risk. What it does mean is that the station has become a working piece of biotech infrastructure, one already used by an actual startup to de-risk a gene therapy candidate, and a genuinely useful tool for isolating the physics of protein misfolding from the confounding effects of gravity that no ground lab can fully remove.
Related Articles
- Biological Aging in Microgravity: What the ISS Reveals About Aging
- Genetic Expression in Microgravity: What Space Reveals About Our DNA
- Protein Crystal Growth in Microgravity: Solving Disease at 400km Altitude
Sources:
- Alzheimer's Association, "2023 Alzheimer's Disease Facts and Figures" — alz.org
- npj Microgravity, "Characterization of amyloid β fibril formation under microgravity conditions" (2020) — pmc.ncbi.nlm.nih.gov/articles/PMC7293247
- Stem Cells Translational Medicine, "Effects of microgravity on human iPSC-derived neural organoids on the International Space Station" (2024) — academic.oup.com/stcltm
- ISS National Lab, "Neurodegenerative Disease Research Launches to the ISS" — issnationallab.org
- ISS National Lab, "How Space Is Opening a Window Into the Brain" — issnationallab.org
- ISS National Lab, "Space-Grown Brain Organoids Help Advance New Neurological Treatment" (Axonis Therapeutics case study) — issnationallab.org
- Neuroscience News, "Space Study Reveals Accelerated Growth of Human Brain Cells" (2024) — neurosciencenews.com
- Garrett-Bakelman et al., "The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight," Science (2019) — science.org
- npj Microgravity, "A review of alterations to the brain during spaceflight and the potential relevance to crew in long-duration space exploration" (2021) — nature.com
Follow new articles
Add SciHub101 to your feed reader to see new science and technology stories.
About the Author
SciHub101 is an independent science and technology publication founded and edited by Buğra Sözeri, a software engineer and app developer based in Türkiye. AI tools assist with drafting and research. Source documentation in the existing archive is uneven, and articles are being reviewed and corrected. The Editorial Team byline identifies editorial responsibility; it does not certify specialist or independent human review. Where we compare products, anything built by our own team is labelled as such — see the editorial guidelines and About page for how corrections and disclosures work.
Related Articles
Apollo 11: First Steps on the Moon and the Dawn of Lunar Science
July 20, 1969: Neil Armstrong and Buzz Aldrin landed on the Moon, returning 21.5 kg of lunar samples that revealed the Moon's geological history and transformed planetary science.
Advanced Materials Processing: Creating Impossible Alloys in Orbit
ISS experiments produce metal alloys and composite materials with properties impossible on Earth, advancing aerospace, electronics, and clean energy.
Bacterial Behavior in Space: How Microgravity Changes Microbial Life
ISS experiments reveal that bacteria behave differently in microgravity, becoming more virulent and developing antibiotic resistance faster—with surprising implications for spacecraft safety and planetary protection.
Biological Aging in Microgravity: What the ISS Reveals About Aging Processes
Spaceflight produces aging-like changes in bone, muscle and the cardiovascular system, most of which largely reverse after return. Here is what the NASA Twins Study and ISS research do, and do not, show about aging.
Bone Loss in Weightlessness: ISS Research on Osteoporosis
ISS astronauts lose bone density faster than aging populations, revealing mechanisms of osteoporosis and informing prevention and treatment strategies.
Cancer Cell Behavior in Zero-G: How Microgravity Changes Tumor Growth
ISS experiments reveal that cancer cells behave differently in microgravity, sometimes becoming more aggressive but also more vulnerable—insights accelerating cancer research.